Interim Half-Year Management Report for the Period Ending 30 June 2025
Gross profit turnaround, reduced cash burn, and stronger balance sheet position the Company for accelerated growth
London, United Kingdom – 24 October 2025 – Rapid Nutrition PLC (Euronext Growth: ALRPD), an international HealthTech and wellness company, today announced the release of its Interim Management Report for the six-month period ended 30 June 2025.
For H1, revenue on an accrual basis was $1,006,548, a 39% increase compared to $724,742 in H1 2024. Of this amount, $893,423 was recorded as trade receivables — representing sales invoiced but not yet collected and expected to be recognized in H2 — while cash revenue received during the period was $113,125.This performance underscores the Company’s continued progress across operations, market expansion, financial stability, and brand development.
The balance sheet also strengthened significantly, with cash increasing to $900,672 (vs. $95,809 in H1 2024), inventories rising to $512,062 (vs. $334,298), and total current assets reaching $2.3 million (vs. $0.9 million).
In addition to a strengthened balance sheet, the Company achieved a gross profit turnaround in H1, reduced its operating cash burn by 11% year-on-year, and increased inventory levels to $512,062 (vs. $334,298 in H1 2024), reflecting proactive stock build-up to meet rising demand and support growth campaigns in key markets. With manufacturing complete, inventory secured, and marketing campaigns ready for deployment, Rapid Nutrition enters H2 from a position of strength.
This result also highlights the Company’s strategic transition away from irregular bulk sales toward a more predictable direct-to-consumer subscription model for its core brands. This subscription-driven approach — with 642 new customers onboarded during the period — is designed to prioritise long-term value creation and customer loyalty over short-term sales. Under this model, subscriptions begin with a complimentary first shipment to maximise conversions, with recurring revenue recognised from month two. Profitability is typically achieved from month three onward.
Key operational highlights:
- Cash position increased nearly tenfold to $900,672.
- Convertible debt fully cleared, further strengthening the balance sheet.
- Successful China launch with 2,800+ units sold in June.
- SystemLS selected for a major U.S. clinical trial, validating product quality.
- Return customer rate in Asia rose to 22% in June.
- Share liquidity improved, with 209% of capital traded during H1.
- Net assets rose to $1.65 million, a fourfold increase since year start.
Management believes the groundwork executed in H1 — particularly the expansion of the subscription base and enhanced financial resilience — will materially benefit results in H2 2025 and over the following 12 months, as campaigns, partnerships, and seasonal demand are activated across Australia, Asia, North America, and Europe.
The full report is available on the company’s Investor Relations website
About Rapid Nutrition: Rapid Nutrition is a global HealthTech company dedicated to advancing wellness through evidence-based, personalized nutrition solutions. Leveraging advanced technologies, AI, and scientific research, the company is committed to optimizing nutrition, improving health outcomes, and fostering sustainable, healthier lifestyles worldwide.
Investor Resources: To receive company news as soon as it is released, subscribe via the Investor Relations section of our website. The Investor tab also provides access to the company’s financial calendar, analyst coverage, and other key shareholder information.
Investor Relations Contact: ir@rnplc.com
Regulatory Information
This Interim Management Report is published pursuant to Rule 4.2 of the Euronext Growth Market Rule Book.
Disclaimer
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).